{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,23]],"date-time":"2025-11-23T15:26:15Z","timestamp":1763911575668},"reference-count":20,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,4,5]]},"DOI":"10.7759\/cureus.57654","type":"journal-article","created":{"date-parts":[[2024,4,5]],"date-time":"2024-04-05T12:46:49Z","timestamp":1712321209000},"source":"Crossref","is-referenced-by-count":2,"title":["Very Low-Dose Sublingual Ketamine for Borderline Personality Disorder and Treatment-Resistant Depression"],"prefix":"10.7759","author":[{"given":"Mitchell","family":"Liester","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rachel","family":"Wilkenson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Barry","family":"Patterson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bertrand","family":"Liang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","article-title":"Borderline personality disorder","volume":"377","author":"Leichsenring F","year":"2023","unstructured":"Leichsenring F, Leibing E, Kruse J, New AS, Leweke F. Borderline personality disorder. Lancet. 2023, 377:74-84.","journal-title":"Lancet"},{"key":"ref2","article-title":"Prevalence and management of treatment-resistant depression","volume":"16","author":"Nemeroff CB","year":"2007","unstructured":"Nemeroff CB. Prevalence and management of treatment-resistant depression. J Clin Psychiat. 2007, 16:17.","journal-title":"J Clin Psychiat"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.3390\/jpm11020155","article-title":"Treatment-resistant depression revisited: a glimmer of hope","volume":"11","author":"Halaris A","year":"2021","unstructured":"Halaris A, Sohl E, Whitham EA. Treatment-resistant depression revisited: a glimmer of hope. J Pers Med. 2021, 11:155. 10.3390\/jpm11020155","journal-title":"J Pers Med"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/j.jad.2019.07.045","article-title":"Inflammatory markers and treatment outcome in treatment resistant depression: a systematic review","volume":"257","author":"Yang C","year":"2019","unstructured":"Yang C, Wardenaar KJ, Bosker FJ, Li J, Schoevers RA. Inflammatory markers and treatment outcome in treatment resistant depression: a systematic review. J Affect Disord. 2019, 257:640-9. 10.1016\/j.jad.2019.07.045","journal-title":"J Affect Disord"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.9758\/cpn.22.1034","article-title":"The role of glutamate underlying treatment-resistant depression","volume":"21","author":"Kim J","year":"2023","unstructured":"Kim J, Kim TE, Lee SH, Koo JW. The role of glutamate underlying treatment-resistant depression. Clin Psychopharmacol Neurosci. 2023, 21:429-46. 10.9758\/cpn.22.1034","journal-title":"Clin Psychopharmacol Neurosci"},{"key":"ref6","doi-asserted-by":"crossref","DOI":"10.1097\/ALN.0b013e3181ed09a2","article-title":"Taming the ketamine tiger","volume":"113","author":"Domino EF","year":"2010","unstructured":"Domino EF, Warner DS. Taming the ketamine tiger. Anesthesiology. 2010, 113:678-84.","journal-title":"Anesthesiology"},{"key":"ref7","unstructured":"FDA alerts health care professionals of potential risks associated with compounded ketamine nasal spray. (2022). Accessed. September 16, 2023: https:\/\/www.fda.gov\/drugs\/human-drug-compounding\/fda-alerts-health-care-professionals-potential-risks-associated-comp...."},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.3389\/fnins.2021.672526","article-title":"Ketamine: neuroprotective or neurotoxic?","volume":"15","author":"Choudhury D","year":"2021","unstructured":"Choudhury D, Autry AE, Tolias KF, Krishnan V. Ketamine: neuroprotective or neurotoxic?. Front Neurosci. 2021, 15:672526. 10.3389\/fnins.2021.672526","journal-title":"Front Neurosci"},{"key":"ref9","article-title":"Antidepressant effects of ketamine in depressed patients","volume":"15","author":"Berman RM","year":"2000","unstructured":"Berman RM, Cappiello A, Anand A, Oren DA, Heninger GR, Charney DS, Krystal JH. Antidepressant effects of ketamine in depressed patients. Biol Psychiat. 2000, 15:351-4.","journal-title":"Biol Psychiat"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1017\/S1461145713000485","article-title":"Antidepressant, mood stabilizing and procognitive effects of very low dose sublingual ketamine in refractory unipolar and bipolar depression","volume":"16","author":"Lara DR","year":"2013","unstructured":"Lara DR, Bisol LW, Munari LR. Antidepressant, mood stabilizing and procognitive effects of very low dose sublingual ketamine in refractory unipolar and bipolar depression. Int J Neuropsychopharmacol. 2013, 16:2111-7. 10.1017\/S1461145713000485","journal-title":"Int J Neuropsychopharmacol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1038\/s41386-023-01540-4","article-title":"A pilot randomized controlled trial of ketamine in borderline personality disorder","volume":"48","author":"Fineberg SK","year":"2023","unstructured":"Fineberg SK, Choi EY, Shapiro-Thompson R, et al.. A pilot randomized controlled trial of ketamine in borderline personality disorder. Neuropsychopharmacology. 2023, 48:991-9. 10.1038\/s41386-023-01540-4","journal-title":"Neuropsychopharmacology"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1016\/j.psychres.2023.115133","article-title":"Real world effectiveness of repeated ketamine infusions for treatment-resistant depression with comorbid borderline personality disorder","volume":"323","author":"Danayan K","year":"2023","unstructured":"Danayan K, Chisamore N, Rodrigues NB, et al.. Real world effectiveness of repeated ketamine infusions for treatment-resistant depression with comorbid borderline personality disorder. Psychiatry Res. 2023, 323:115133. 10.1016\/j.psychres.2023.115133","journal-title":"Psychiatry Res"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.24632","article-title":"\"Esketamine\" in borderline personality disorder: a look beyond suicidality","volume":"14","author":"Nandan NK","year":"2022","unstructured":"Nandan NK, Soni PK, Parsaik A, Hashmi A. \"Esketamine\" in borderline personality disorder: a look beyond suicidality. Cureus. 2022, 14:e24632. 10.7759\/cureus.24632","journal-title":"Cureus"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1097\/JCP.0000000000001642","article-title":"Ketamine as a treatment option for severe borderline personality disorder: a case report","volume":"43","author":"Rogg H","year":"2023","unstructured":"Rogg H, Avram M, M\u00fcller F, Junghanns K, Borgwardt S, Zurowski B. Ketamine as a treatment option for severe borderline personality disorder: a case report. J Clin Psychopharmacol. 2023, 43:64-5. 10.1097\/JCP.0000000000001642","journal-title":"J Clin Psychopharmacol"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.12264","article-title":"The absolute bioavailability of racemic ketamine from a novel sublingual formulation","volume":"77","author":"Rolan P","year":"2014","unstructured":"Rolan P, Lim S, Sunderland V, Liu Y, Molnar V. The absolute bioavailability of racemic ketamine from a novel sublingual formulation. Br J Clin Pharmacol. 2014, 77:1011-6. 10.1111\/bcp.12264","journal-title":"Br J Clin Pharmacol"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1523\/JNEUROSCI.19-09-03307.1999","article-title":"Cytosolic Ca2+ changes during in vitro ischemia in rat hippocampal slices: major roles for glutamate and Na+-dependent Ca2+ release from mitochondria","volume":"19","author":"Zhang Y","year":"1999","unstructured":"Zhang Y, Lipton P. Cytosolic Ca2+ changes during in vitro ischemia in rat hippocampal slices: major roles for glutamate and Na+-dependent Ca2+ release from mitochondria. J Neurosci. 1999, 19:3307-15. 10.1523\/JNEUROSCI.19-09-03307.1999","journal-title":"J Neurosci"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1523\/JNEUROSCI.6078-08.2009","article-title":"Positive AMPA receptor modulation rapidly stimulates BDNF release and increases dendritic mRNA translation","volume":"29","author":"Jourdi H","year":"2009","unstructured":"Jourdi H, Hsu YT, Zhou M, Qin Q, Bi X, Baudry M. Positive AMPA receptor modulation rapidly stimulates BDNF release and increases dendritic mRNA translation. J Neurosci. 2009, 29:8688-97. 10.1523\/JNEUROSCI.6078-08.2009","journal-title":"J Neurosci"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1038\/mp.2013.87","article-title":"Ketamine: synaptogenesis, immunomodulation and glycogen synthase kinase-3 as underlying mechanisms of its antidepressant properties","volume":"18","author":"Zunszain PA","year":"2013","unstructured":"Zunszain PA, Horowitz MA, Cattaneo A, Lupi MM, Pariante CM. Ketamine: synaptogenesis, immunomodulation and glycogen synthase kinase-3 as underlying mechanisms of its antidepressant properties. Mol Psychiatry. 2013, 18:1236-41. 10.1038\/mp.2013.87","journal-title":"Mol Psychiatry"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1097\/CCM.0b013e318253563c","article-title":"Ketamine alters the neurogenesis of rat cortical neural stem progenitor cells","volume":"40","author":"Dong C","year":"2012","unstructured":"Dong C, Rovnaghi CR, Anand KJ. Ketamine alters the neurogenesis of rat cortical neural stem progenitor cells. Crit Care Med. 2012, 40:2407-16. 10.1097\/CCM.0b013e318253563c","journal-title":"Crit Care Med"},{"key":"ref20","article-title":"NMDA neurotransmission as a critical mediator of borderline personality disorder","volume":"1","author":"Grosjean B","year":"2007","unstructured":"Grosjean B, Tsai GE. NMDA neurotransmission as a critical mediator of borderline personality disorder. J Psychiatr Neurosci. 2007, 1:103-15.","journal-title":"J Psychiatr Neurosci"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/241649-very-low-dose-sublingual-ketamine-for-borderline-personality-disorder-and-treatment-resistant-depression","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,5]],"date-time":"2024-04-05T12:46:55Z","timestamp":1712321215000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/241649-very-low-dose-sublingual-ketamine-for-borderline-personality-disorder-and-treatment-resistant-depression"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,5]]},"references-count":20,"URL":"https:\/\/doi.org\/10.7759\/cureus.57654","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,4,5]]}}}